Form 4 for URGN UroGen Pharma Ltd.
Accepted 2023-02-02 00:00:00 ET · period of report 2023-01-31 · accession 0001437749-23-002358 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-02 | 2023-01-31 | URGN | Barrett Elizabeth A. | CEO | M - OptEx | — | +18.3K | 313.4K | +6% | — |
| DM | 2023-02-02 | 2023-01-31 | URGN | Barrett Elizabeth A. | CEO | A - Grant | $0.00 | +300.0K | 75.0K | New | $0 |
| DM | 2023-02-02 | 2023-01-31 | URGN | Barrett Elizabeth A. | CEO | M - OptEx | $0.00 | -18.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-01-31 | M | A | 13,333 | — | 326,691 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. |
| 2 | Common | Ordinary Shares | 2023-01-31 | M | A | 5,000 | — | 313,358 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. |
| 3 | Derivative | Performance Stock Units | 2023-01-31 | A | A | 100,000 | $0.00 | 100,000 | D | — · — to — | 100,000 Ordinary Shares | (F8) The performance stock units were approved by the Board of Directors of the Issuer on January 31, 2023. If the performance stock units are not ratified by the Issuer's shareholders at the Issuer's 2023 annual general meeting, the performance stock units will terminate. (F6) Each performance stock unit ("PSU") represents a contingent right to receive one ordinary share of the Issuer. (F7) All shares underlying the performance stock units will vest upon achievement of a corporate milestone event. |
| 4 | Derivative | Employee Stock Option (right to buy) | 2023-01-31 | A | A | 125,000 | $0.00 | 125,000 | D | $10.39 · — to 2033-01-31 | 125,000 Ordinary Shares | (F5) 1/3 of the shares underlying the stock options will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. |
| 5 | Derivative | Restricted Stock Units | 2023-01-31 | A | A | 75,000 | $0.00 | 75,000 | D | — · — to — | 75,000 Ordinary Shares | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. (F4) 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. |
| 6 | Derivative | Restricted Stock Units | 2023-01-31 | M | D | 13,333 | $0.00 | 13,334 | D | — · — to — | 13,333 Ordinary Shares | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. (F3) The reporting person was granted restricted stock units ("RSUs") on January 31, 2021 representing 40,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2022. |
| 7 | Derivative | Restricted Stock Units | 2023-01-31 | M | D | 5,000 | $0.00 | 0 | D | — · — to — | 5,000 Ordinary Shares | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. (F2) The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 15,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2021. |